IIL to set up new viral antigen manufacturing facility in Telangana with Rs 75 cr investment

Hyderabad, Nov 25 (Agency) Indian Immunological Ltd (IIL), the market leader in veterinary biologicals, on Wednesday announced the ground-breaking of a new viral antigen manufacturing facility in Phase III of Genome Valley, Karkapatla, Ranga Reddy District of Telangana. With investment of INR 75 crores in the upcoming facility, ILL expected to increase its capacity to supply additional quantities of high-quality and safe vaccines. The new facility will be specially designed as a multiproduct facility and to cater to the need for viral vaccines in the pipeline that includes Dengue, Zika and Varicella, Hyderabad-based veterinary biological company said in a release here.

Our new facility is spread across 2000 square meters and is very well equipped for world class GMP production of Biosafety level 2 and 3 vaccines (BSL-2 and BSL-3). The company also plans to utilize the cutting-edge facility to manufacture COVID-19 vaccines post completion of its R&D with Griffith University, Australia. The Company also inaugurated a new Sterile Filling Facility that was commissioned last year at an additional investment of INR 75 crores. This facility will increase IIL’s capacity to supply lifesaving vaccines such as the Anti Rabies Vaccine (ARV) – Abhayrab™. As a part of the expansion plan, IIL will add over 150 new positions, bringing its total staff strength close to 1,500. The new facility will boost the production capacity by over 35 per cent and increase the supply capacity to key markets where rabies vaccine is critically needed.

IIL Managing Director Dr. K Anand Kumar, said as we mark as one of the major players on the pediatric and rabies vaccine, this expansion of our manufacturing facility is our commitment to securing a healthy and sustainable future. The total investment of over INR 150 crores in in the same direction of our vision to increase the production capacities to ensure a reliable and affordable supply of high-quality vaccines to larger communities. “This facility has been specially designed to cater to the need for various viral vaccines and it will boost our manufacturing capacity by 35%. The new plant is expected to be ready for operation by October 2021,” said Dr. Prasanna Deshpande, Deputy Managing Director, IIL. IIL has 4 manufacturing facilities at various locations – Karkapatla (Telangana) – Human Vaccines & Animal Health Formulations; Ooty (Tamil Nadu )– Anti Rabies production unit; Hyderabad ( Telangana) – Human Biologicals Unit (Gachibowli) and animal vaccines unit; Dargaville (New Zealand – New Bovine Serum. IIL exports various Human and animal vaccines to over 50 countries and currently employs around 1,300 people.